Three integrated systems — all built on the same transcriptomic foundation. Disease, drugs, and the models that connect them — and every molecule we test feeds back in, so the platform sharpens with each cycle.
Every disease leaves a transcriptomic signature — a pattern across thousands of genes, in specific cell types. Most platforms measure a handful; we measure them all, in patient-derived tissue at single-cell resolution. Then we build validated signatures — fusing expression, human genetics, and mechanism — so we target what causes a disease, not just what shifts with it.
We don't screen blindly. The disease signature tells us which compounds are worth profiling — then DRUG-seq measures the full transcriptomic response of each, at dose, in disease-relevant human cells. A drug doesn't just hit one target: every compound changes the expression of thousands of genes, intended and unintended. We capture the whole profile.
Most drug screens run in immortalized cancer cell lines — convenient, but disconnected from the biology that matters. We profile compounds in human-derived, disease-relevant cells. The response we measure is the response that matters.
Machine-learning models trained on the union of both atlases. The Conductor asks: what compounds, alone or in combination, push a diseased cell back toward health? It surfaces reversal candidates no human could enumerate by hand.
Conductor AI predicts which molecules should produce a target transcriptomic profile, then screens billions of on-demand, synthesizable compounds in silico — narrowing a library no chemist could enumerate by hand to a shortlist worth synthesizing.
Enter repurposing trials fastest. Validate the matching method against established safety.
Carry existing safety data forward. New indications discovered through the Drug-Gene Atlas.
Discovered by Conductor AI for a target signature. Deepest therapeutic potential.
Together, the three tiers generate staggered clinical proof-of-concept — validating the platform while advancing programs. Capital flows to the matches the data supports, and away from the ones it doesn't.